Global Vaccine Combinations Market – Industry Trends and Forecast to 2029

Market Analysis and Size

Individual diphtheria, tetanus, and pertussis (DTP) vaccinations were combined into a single product to generate combination vaccines for protection against numerous diseases. Vaccines are products that work with the body's own immune system to build up protection against harmful microorganisms, reducing the chance of sickness. Vaccines for life-threatening diseases have been developed, averting approximately 2-3 million fatalities each year from diseases including tetanus, diphtheria, pertussis, measles, and influenza.

Data Bridge Market Research analyses that the vaccine combinations? market was valued at USD 5.94 billion in 2021 and is expected to reach USD 9.76 billion by 2029, registering a CAGR of 6.40% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Vaccines cause an antibody-antigen reaction, which aids in the development of resistance to the pathogen. Recombinant vaccines, conjugate vaccinations, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and other vaccines are types of vaccines. Vaccine combinations integrate antigens that protect against numerous strains of infectious pathogens that cause the same disease. This cuts down on the number of shots needed to keep some disease under control.

Vaccine Combinations Market Dynamics

Drivers

• Increasing prevalence of infectious diseases

The rising prevalence of infectious diseases is anticipated to influence the vaccine combinations? market's growth. As per the world health organization (WHO), nearly 85 percent of infants (116 million) worldwide received three doses of the diphtheria-tetanus-pertussis (DTP3) vaccination, which protects them from infectious diseases that can cause serious illness, disability, or death. In addition, 125 nations achieved DTP3 vaccination coverage of at least 90% in 2019.

• Rising awareness about immunization

The increasing awareness about immunization and vaccination benefits in emerging regions is expected to flourish the 'market's growth rate during the forecast period of 2022-2029. With improved healthcare awareness, the focus on immunization has shifted significantly, and a variety of government agencies are working to achieve this goal.  For instance, Immunize Australia is an Australian government programme that helps people buy immunizations. The National Immunization Program (NIP) Schedule is also implemented, which now contains immunizations for 16 illnesses, including diphtheria, measles and whooping cough (pertussis), as well as vaccines that have just recently been discovered, such as the meningococcal ACWY and HPV vaccines. From birth, every Australian must adhere to this programme.

Furthermore, rising healthcare expenditure and growing incidences of pneumonia will expand the vaccine combinations? market. Additionally, increasing geriatric population and favourable reimbursement policies will result in the expansion of vaccine combinations? market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. Also, company investments and government funding are encouraging R&D sector for launching novel products. This will provide beneficial opportunities for the vaccine combinations? market growth.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the vaccine combinations? market growth during the forecast period.

Restraints/Challenges

• Misinformation about vaccine

Human nature attempts to reason, better grasp, and fill in the gaps when there are knowledge gaps or unresolved science, which leads to misinformation. According to new data, approximately 6,000 people were hospitalised around the world in the first three months of 2020 as a result of coronavirus misinformation, according to new data. Nearly 800 people may have perished as a result of COVID-19 misinformation during this time. Governments, funding agencies, vaccine makers and suppliers, and other stakeholders are all concerned about vaccination misinformation and disinformation. Due to vaccination misinformation, poor acceptance rates result in decreased market penetration of effective and safe vaccines, which could have a negative impact on the market.

On the other hand, the high cost associated with the vaccine combinations is anticipated to obstruct the 'market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the vaccine combinations? market. Additionally, side effects of vaccine combinations? and stringent government regulations will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This vaccine combinations? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the vaccine combinations? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Vaccine combinations? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, and adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Vaccine Combinations Market

The pandemic of COVID-19 altered the market dynamics for vaccinations. The traditional vaccination market shrank slightly in 2020, as the focus changed from common vaccines to COVID-19 vaccines. As per the UNICEF COVID-19 Vaccine Market Dashboard, at least one country regulatory body has licensed 28 COVID-19 vaccines for use globally. Eight vaccines have been added to the World Health Organization's Emergency Use List (EUL). In total, 21.1 billion doses of COVID-19 vaccinations have been secured worldwide.

Recent Development

• In October 2021, Pfizer and BioNTech had announced the U.S. Food and Drug Administration (FDA) approval for emergency use of a COVID-19 vaccine in children ages 5 through 11 Years. The vaccination should be given in two 10-g doses 21 days apart to this age group. The 10-g dose level was chosen after thorough consideration of the evidence on safety, tolerability, and immunogenicity. This is the first COVID-19 vaccine to be approved in the United States for children aged 5 to 11.

Global Vaccine Combinations Market Scope

The vaccine combinations? market is segmented on the basis of drug type, application, product type, demographic, type, kind, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Type

• Adacel
• Vaxelis
• Twinrix
• Quadracel
• M-M-R II
• Comvax
• Others

Application

• Diphtheria Prophylaxis
• Haemophilus influenzae Prophylaxis
• Hepatitis A Prophylaxis
• Hepatitis B Prevention
• Mumps Prophylaxis
• Measles Prophylaxis
• Poliomyelitis Prophylaxis
• Pertussis Prophylaxis
• Rubella Prophylaxis
• Tetanus Prophylaxis
• Others

Product Type

• Two Combinations
• Three Combinations
• Four Combinations
• Six Combinations

Demographic

• Adult
• Pediatrics

Type

• Subunit
• Recombinant
• Polysaccharide and Conjugate Vaccines
• Live-Attenuated Vaccines
• Inactivated Vaccines
• Toxoid Vaccines
• DNA Vaccines

Kind

• Routine Vaccine
• Recommended Vaccine
• Required Vaccine

Route of Administration

• Injectable
• Oral
• Nasal

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Vaccine Combinations Market Regional Analysis/Insights

The vaccine combinations? market is analysed and market size insights and trends are provided by country, drug type, application, product type, demographic, type, kind, route of administration, end-users and distribution channel as referenced above.

The countries covered in the vaccine combinations? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the vaccine combinations? market because of the rising number of research and development activities in this region. Additionally, growing presence of major key players and well-established healthcare infrastructure will further propel the 'market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to rising healthcare expenditure and improvements in healthcare infrastructure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Vaccine Combinations Market Share Analysis

The vaccine combinations? market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to vaccine combinations? market.

Some of the major players operating in the vaccine combinations? market are:

• Bio Farma (Indonesia)
• Bharat Biotech (India)
• Serum Institute of India Pvt. Ltd. (India)
• Biological E Limited (India)
• Novartis AG (Switzerland)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Takeda Pharmaceutical Company Limited (Japan)
• Johnson & Johnson Private Limited (US)
• Sanofi (France)
• Merck & Co., Inc. (US)
• Baxter (US)
• CSL Limited (Australia)
• Abbott (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• DAIICHI SANKYO COMPANY, LIMITED (Japan)
• EMERGENT (US)
• Dynavax Technologies (US)
• Valneva SE (France)
• Bavarian Nordic A/S (Denmark)
• Panacea Biotec (India)
• Mitsubishi Tanabe Pharma Corporation (Japan)

SKU-68376